Skip to main content

Advertisement

SpringerLink
Log in

Emerging Therapies in Relapsed and Refractory Hodgkin Lymphoma: What Comes Next After Brentuximab Vedotin and PD-1 Inhibition?

  • T-Cell and Other Lymphoproliferative Malignancies (J Zain, Section Editor)
  • Published:
Current Hematologic Malignancy Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

The standard of care for relapsed/refractory (r/r) Hodgkin lymphoma (HL) patients is autologous stem cell transplantation (ASCT) for patients in a first or second relapse. However, a significant number of patients with r/r HL are either medically ineligible for ASCT or relapse post-ASCT. In recent years, significant advances have been made in the management of r/r HL with the introduction of the anti-CD30 antibody-drug conjugate (ADC) brentuximab vedotin (BV) and the anti-PD1 checkpoint inhibitors (CPI) nivolumab and pembrolizumab. Nonetheless, despite excellent tolerability and high response rates, the large majority of patients will ultimately progress on these agents. Allogeneic hematopoietic cell transplantation (alloHCT) has offered a potentially curative option for these patients, but high rates of morbidity and mortality have limited its application, and disease relapse is also common post-alloHCT. Thus, effective therapy for HL patients who fail BV and CPI therapy remains an unmet need. This review will cover different treatment strategies for HL patients in this setting with a focus on emerging new therapies.

Recent Findings

Investigators have explored methods with the potential to restore sensitivity to BV and CPIs in patients who develop resistance. Additionally, promising new therapeutics are emerging, such as CD25-directed ADC therapy and CD30-directed chimeric antigen receptor (CAR) T cells.

Summary

While no consensus guidelines exist for the management of HL patients refractory to BV and checkpoint blockade, potential novel strategies and therapeutics are currently under investigation in hopes of expanding the treatment landscape for this challenging patient population.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Engert A, Plütschow A, Eich HT, Lohri A, Dörken B, Borchmann P, et al. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med. 2010;363(7):640–52.

    Article  CAS  PubMed  Google Scholar 

  2. Eich HT, Diehl V, Görgen H, Pabst T, Markova J, Debus J, et al. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 Trial. J Clin Oncol. 2010;28(27):4199–206.

    Article  PubMed  Google Scholar 

  3. Gordon LI, Hong F, Fisher RI, Bartlett NL, Connors JM, Gascoyne RD, et al. Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496). J Clin Oncol. 2013;31(6):684–91.

    Article  PubMed  Google Scholar 

  4. Merli F, Luminari S, Gobbi PG, Cascavilla N, Mammi C, Ilariucci F, et al. Long-term results of the HD2000 trial comparing ABVD versus BEACOPP versus COPP-EBV-CAD in untreated patients with advanced Hodgkin lymphoma: a study by Fondazione Italiana Linfomi. J Clin Oncol. 2016;34(11):1175–81.

    Article  CAS  PubMed  Google Scholar 

  5. Kumar A, Burger IA, Zhang Z, Drill EN, Migliacci JC, Ng A, et al. Definition of bulky disease in early stage Hodgkin lymphoma in computed tomography era: prognostic significance of measurements in the coronal and transverse planes. Haematologica. 2016;101(10):1237–43.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Hutchings M. PET-adapted treatment of Hodgkin lymphoma. Blood. 2019;134(15):1200–1.

    Article  CAS  PubMed  Google Scholar 

  7. Stephens DM, Li H, Schöder H, Straus DJ, Moskowitz CH, LeBlanc M, et al. Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III/IV Hodgkin lymphoma. Blood. 2019;134(15):1238–46.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Schmitz N, Pfistner B, Sextro M, Sieber M, Carella AM, Haenel M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin’s disease: a randomised trial. Lancet. 2002;359(9323):2065–71.

    Article  CAS  PubMed  Google Scholar 

  9. Josting A, Reiser M, Rueffer U, Salzberger B, Diehl V, Engert A. Treatment of primary progressive Hodgkin's and aggressive non-Hodgkin's lymphoma: is there a chance for cure? J Clin Oncol. 2000;18(2):332–9.

    Article  CAS  PubMed  Google Scholar 

  10. Moskowitz CH, Nademanee A, Masszi T, Agura E, Holowiecki J, Abidi MH, et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;385(9980):1853–62.

    Article  CAS  PubMed  Google Scholar 

  11. Majhail NS, Weisdorf DJ, Defor TE, Miller JS, McGlave PB, Slungaard A, et al. Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin's lymphoma. Biol Blood Marrow Transplant. 2006;12(10):1065–72.

    Article  PubMed  Google Scholar 

  12. Moskowitz AJ, Perales MA, Kewalramani T, Yahalom J, Castro-Malaspina H, Zhang Z, et al. Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma. Br J Haematol. 2009;146(2):158–63.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Martínez C, Canals C, Sarina B, Alessandrino EP, Karakasis D, Pulsoni A, et al. Identification of prognostic factors predicting outcome in Hodgkin's lymphoma patients relapsing after autologous stem cell transplantation. Ann Oncol. 2013;24(9):2430–4.

    Article  PubMed  Google Scholar 

  14. Mei M, Thomas S, Chen R. Management of relapsed or refractory hodgkin lymphoma with second-generation antibody-drug conjugates: focus on brentuximab vedotin. BioDrugs. 2014;28(3):245–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol. 2012;30(18):2183–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Moskowitz CH, Walewski J, Nademanee A, Masszi T, Agura E, Holowiecki J, et al. Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse. Blood. 2018;132(25):2639–42.

    Article  CAS  PubMed  Google Scholar 

  17. Connors JM, Jurczak W, Straus DJ, Ansell SM, Kim WS, Gallamini A, et al. Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin's lymphoma. N Engl J Med. 2018;378(4):331–44.

    Article  CAS  PubMed  Google Scholar 

  18. Younes A, Santoro A, Shipp M, Zinzani PL, Timmerman JM, Ansell S, et al. Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol. 2016;17(9):1283–94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Chen R, Zinzani PL, Fanale MA, Armand P, Johnson NA, Brice P, et al. Phase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic Hodgkin lymphoma. J Clin Oncol. 2017;35(19):2125–32.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Chen R, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, et al. Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2016;128(12):1562–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Armand P, Engert A, Younes A, Fanale M, Santoro A, Zinzani PL, et al. Nivolumab for relapsed/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 Trial. J Clin Oncol. 2018;36(14):1428–39.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Chen R, Hou J, Newman E, Kim Y, Donohue C, Liu X, et al. CD30 Downregulation, MMAE resistance, and MDR1 upregulation are all associated with resistance to brentuximab vedotin. Mol Cancer Ther. 2015;14(6):1376–84.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Armand P, Kuruvilla J, Michot J-M, Ribrag V, Zinzani PL, Zhu Y, et al. KEYNOTE-013 4-year follow-up of pembrolizumab in classical Hodgkin lymphoma after brentuximab vedotin failure. Blood Adv. 2020;4(12):2617–22.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Chen R, Palmer JM, Thomas SH, Tsai NC, Farol L, Nademanee A, et al. Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2012;119(26):6379–81.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Merryman RW, Kim HT, Zinzani PL, Carlo-Stella C, Ansell SM, Perales MA, et al. Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma. Blood. 2017;129(10):1380–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Rashidi A, Ebadi M, Cashen AF. Allogeneic hematopoietic stem cell transplantation in Hodgkin lymphoma: a systematic review and meta-analysis. Bone Marrow Transplant. 2016;51(4):521–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Spina F, Radice T, De Philippis C, Soldarini M, Di Chio MC, Dodero A, et al. Allogeneic transplantation for relapsed and refractory Hodgkin lymphoma: long-term outcomes and graft-versus-host disease-free/relapse-free survival. Leuk Lymphoma. 2019;60(1):101–9.

    Article  PubMed  Google Scholar 

  28. Mei M, Chen R. How to approach a Hodgkin lymphoma patient with relapse after autologous SCT: allogeneic SCT. Clin Lymphoma Myeloma Leuk. 2018;18(1):26–33.

    Article  PubMed  Google Scholar 

  29. Kharfan-Dabaja MA, Hamadani M, Sibai H, Savani BN. Managing Hodgkin lymphoma relapsing after autologous hematopoietic cell transplantation: a not-so-good cancer after all! Bone Marrow Transplant. 2014;49(5):599–606.

    Article  CAS  PubMed  Google Scholar 

  30. Casadei B, Broccoli A, Stefoni V, Pellegrini C, Marangon M, Morigi A, et al. PD-1 blockade as bridge to allogeneic stem cell transplantation in relapsed/refractory Hodgkin lymphoma patients: a retrospective single center case series. Haematologica. 2019;104(11):e521–e2.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Ahmed S, Ghosh N, Ahn KW, Khanal M, Litovich C, Mussetti A, et al. Impact of type of reduced-intensity conditioning regimen on the outcomes of allogeneic haematopoietic cell transplantation in classical Hodgkin lymphoma. Br J Haematol. 2020;190(4):573–582.

  32. Chen R, Herrera AF, Hou J, Chen L, Wu J, Guo Y, et al. Inhibition of MDR1 overcomes resistance to brentuximab vedotin in Hodgkin lymphoma. Clin Cancer Res. 2020;26(5):1034–1044.

  33. Wei W, Lin Y, Song Z, Xiao W, Chen L, Yin J, et al. A20 and RBX1 regulate brentuximab vedotin sensitivity in Hodgkin lymphoma models. Clin Cancer Res. 2020;26(15):4093–106.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Veldman J, Visser L, Avd B, Diepstra A. Primary and acquired resistance mechanisms to immune checkpoint inhibition in Hodgkin lymphoma. Cancer Treat Rev. 2020;82:101931.

  35. Ghoneim HE, Fan Y, Moustaki A, Abdelsamed HA, Dash P, Dogra P, et al. De novo epigenetic programs inhibit PD-1 blockade-mediated T cell rejuvenation. Cell. 2017;170(1):142–57.e19.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Pauken KE, Sammons MA, Odorizzi PM, Manne S, Godec J, Khan O, et al. Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade. Science. 2016;354(6316):1160–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Falchi L, Sawas A, Deng C, Amengual JE, Colbourn DS, Lichtenstein EA, et al. High rate of complete responses to immune checkpoint inhibitors in patients with relapsed or refractory Hodgkin lymphoma previously exposed to epigenetic therapy. J Hematol Oncol. 2016;9(1):132.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Nie J, Wang C, Liu Y, Yang Q, Mei Q, Dong L, et al. Addition of low-dose decitabine to anti–PD-1 antibody camrelizumab in relapsed/refractory classical Hodgkin lymphoma. J Clin Oncol. 2019;37(17):1479–89.

    Article  CAS  PubMed  Google Scholar 

  39. Herrera AF, Chen L, Popplewell LL, Budde LE, Mei M, Armenian SH, et al. Preliminary results from a phase I trial of pembrolizumab plus vorinostat in patients with relapsed or refractory diffuse large B-cell lymphoma, Follicular Lymphoma, and Hodgkin Lymphoma. Blood. 2019;134(Supplement_1):759.

    Article  Google Scholar 

  40. Wang X, Waschke BC, Woolaver RA, Chen SMY, Chen Z, Wang JH. HDAC inhibitors overcome immunotherapy resistance in B-cell lymphoma. Protein Cell. 2020;11(7):472–82.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Rossi C, Gilhodes J, Maerevoet M, Herbaux C, Morschhauser F, Brice P, et al. Efficacy of chemotherapy or chemo-anti-PD-1 combination after failed anti-PD-1 therapy for relapsed and refractory Hodgkin lymphoma: a series from lysa centers. Am J Hematol. 2018;93(8):1042–9.

    Article  CAS  Google Scholar 

  42. Mikhailova NB, Lepik KV, Kondakova EV, Kotselyabina PV, Kozlov AV, Zalyalov YR, et al. Combination of nivolumab and bendamustine in patients with relapsed or refractory classical Hodgkin lymphoma. Hematol Oncol. 2019;37(S2):494–5.

    Article  Google Scholar 

  43. Merryman RW, Carreau NA, Advani RH, Spinner MA, Herrera AF, Chen R, et al. Impact of treatment beyond progression with immune checkpoint blockade in Hodgkin lymphoma. Oncologist. 2020;25(6):e993–e7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. De Goycoechea D, Stalder G, Martins F, Duchosal MA. Immune checkpoint inhibition in classical Hodgkin lymphoma: from early achievements towards new perspectives. J Oncol. 2019;2019:9513701.

    Article  PubMed  PubMed Central  Google Scholar 

  45. Hamadani M, Collins GP, Samaniego F, Spira AI, Davies A, Radford J, et al. Phase 1 Study of Adct-301 (Camidanlumab Tesirine), a novel pyrrolobenzodiazepine-based antibody drug conjugate, in relapsed/refractory classical Hodgkin lymphoma. Blood. 2018;132(Supplement 1):928.

    Article  Google Scholar 

  46. Bosler DS, Douglas-Nikitin VK, Harris VN, Smith MD. Detection of T-regulatory cells has a potential role in the diagnosis of classical Hodgkin lymphoma. Cytometry B Clin Cytom. 2008;74B(4):227–35.

    Article  CAS  Google Scholar 

  47. Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. N Engl J Med. 2017;377(26):2531–44.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Schuster SJ, Svoboda J, Chong EA, Nasta SD, Mato AR, Anak Ö, et al. Chimeric antigen receptor T cells in refractory B-cell lymphomas. N Engl J Med. 2017;377(26):2545–54.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2020;382(14):1331–42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Grover NS, Savoldo B. Challenges of driving CD30-directed CAR-T cells to the clinic. BMC Cancer. 2019;19(1):203.

    Article  PubMed  PubMed Central  Google Scholar 

  51. Hombach A, Heuser C, Sircar R, Tillmann T, Diehl V, Pohl C, et al. An anti-CD30 chimeric receptor that mediates CD3-zeta-independent T-cell activation against Hodgkin's lymphoma cells in the presence of soluble CD30. Cancer Res. 1998;58(6):1116–9.

    CAS  PubMed  Google Scholar 

  52. Hombach A, Heuser C, Sircar R, Tillmann T, Diehl V, Pohl C, et al. Characterization of a chimeric T-cell receptor with specificity for the Hodgkin's lymphoma-associated CD30 antigen. J Immunother. 1999;22(6):473–80.

    Article  CAS  PubMed  Google Scholar 

  53. Dotti G, Gottschalk S, Savoldo B, Brenner MK. Design and development of therapies using chimeric antigen receptor-expressing T cells. Immunol Rev. 2014;257(1):107–26.

    Article  CAS  PubMed  Google Scholar 

  54. Savoldo B, Rooney CM, Di Stasi A, Abken H, Hombach A, Foster AE, et al. Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease. Blood. 2007;110(7):2620–30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Hombach AA, Görgens A, Chmielewski M, Murke F, Kimpel J, Giebel B, et al. Superior therapeutic index in lymphoma therapy: CD30(+) CD34(+) hematopoietic stem cells resist a chimeric antigen receptor T-cell attack. Mol Ther. 2016;24(8):1423–34.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Hombach AA, Abken H. Shared target antigens on cancer cells and tissue stem cells: go or no-go for CAR T cells? Expert Rev Clin Immunol. 2017;13(2):151–5.

    Article  CAS  PubMed  Google Scholar 

  57. Wang CM, Wu ZQ, Wang Y, Guo YL, Dai HR, Wang XH, et al. Autologous T cells expressing CD30 chimeric antigen receptors for relapsed or refractory Hodgkin lymphoma: an open-label phase I trial. Clin Cancer Res. 2017;23(5):1156–66.

    Article  CAS  PubMed  Google Scholar 

  58. Ramos CA, Grover NS, Beaven AW, Lulla PD, Wu MF, Ivanova A, et al. Anti-CD30 CAR-T cell therapy in relapsed and refractory Hodgkin lymphoma. J Clin Oncol. 2020:Jco2001342.

  59. Ramos CA, Ballard B, Zhang H, Dakhova O, Gee AP, Mei Z, et al. Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes. J Clin Oncol. 2020;38(32):3794–3804.

  60. Ramos CA, Bilgi M, Gerken CP, Dakhova O, Mei Z, Grilley BJ, et al. CD30-chimeric antigen receptor (CAR) T cells for therapy of Hodgkin lymphoma (HL). Blood. 2018;132(Supplement 1):680.

    Article  Google Scholar 

  61. Ramos CA, Torrano V, Bilgi M, Gerken C, Dakhova O, Mei Z, et al. CD30-Chimeric antigen receptor (CAR) T cells for therapy of Hodgkin lymphoma (HL). Hematol Oncol. 2019;37(S2):168.

    Article  Google Scholar 

  62. Grover NS, Park SI, Ivanova A, Eldridge P, McKay K, Cheng C, et al. A Phase Ib/II Study of anti-CD30 chimeric antigen receptor T cells for relapsed/refractory CD30+ lymphomas. Biol Blood Marrow Transplant. 2019;25(3, Supplement):S66.

    Article  Google Scholar 

  63. Wang D, Zeng C, Xu B, Xu JH, Wang J, Jiang LJ, et al. Anti-CD30 chimeric antigen receptor T cell therapy for relapsed/refractory CD30(+) lymphoma patients. Blood Cancer J. 2020;10(1):8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  64. Karlsson H, Svensson E, Gigg C, Jarvius M, Olsson-Strömberg U, Savoldo B, et al. Evaluation of intracellular signaling downstream chimeric antigen receptors. PLoS One. 2015;10(12):e0144787.

    Article  PubMed  PubMed Central  Google Scholar 

  65. Ramos CA, Rouce R, Robertson CS, Reyna A, Narala N, Vyas G, et al. In vivo fate and activity of second- versus third-generation CD19-specific CAR-T cells in B cell non-Hodgkin's lymphomas. Mol Ther. 2018;26(12):2727–37.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Comprehensive Cancer Center, University of California Davis, Sacramento, CA, USA

    Tamer Othman

  2. Toni Stephenson Lymphoma Center, Department of Hematology and Hematopoietic Cell Transplant, City of Hope National Medical Center, 1500 East Duarte Road, Duarte, CA, 91010, USA

    Alex Herrera & Matthew Mei

Authors
  1. Tamer Othman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alex Herrera
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Matthew Mei
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Matthew Mei.

Ethics declarations

Conflict of Interest

Tamer Othman declares no potential conflicts of interest.

Alex Herrera—Consulting or Advisory Role, Bristol-Myers Squibb; Merck; Seattle Genetics; Karyopharm, Research Funding, Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Merck (Inst); Seattle Genetics (Inst); ADC Therapeutics (Inst); Kite Pharma/Gilead (Inst), Travel, Accommodations, Expenses, Bristol-Myers Squibb

Matthew Mei—Consulting or Advisory Role, Morphosys; Sanofi Genzyme

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article belongs to the Topical Collection on T-Cell and Other Lymphoproliferative Malignancies

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Othman, T., Herrera, A. & Mei, M. Emerging Therapies in Relapsed and Refractory Hodgkin Lymphoma: What Comes Next After Brentuximab Vedotin and PD-1 Inhibition?. Curr Hematol Malig Rep 16, 1–7 (2021). https://doi.org/10.1007/s11899-020-00603-3

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11899-020-00603-3

Keywords

Search

Navigation